CASE RECORD1:24-cv-08821•U.S. District Court, S.D.N.Y. (Manhattan)
IP PATENT_INFRINGEMENTLITIGATION ACTIVE
Apex BioTherapeutics Inc. v. Meridian Pharma Global Corp.
Presiding Judge: Hon. Katherine Polk FaillaFiling Date: 2024-03-12Est. Trial: 2025-11-15
Action Summary
Patent infringement suit asserting willful violation of U.S. Patent No. 10,482,911 covering targeted mRNA nanoparticle delivery formulations. Defendant continues commercial distribution of infringing therapy.
Asserted Patents / Causes
U.S. Patent No. 10,482,911
Lipid-Nanoparticle Conjugates
Primary Defense Arguments
35 U.S.C. § 103 Obviousness
12(b)(6) Dismissal Denied
Defendant Solvency & Verified Commercial Coverage
Audited insurance limits verify that defendant Meridian Pharma Global possesses adequate liquidity and policy coverage to satisfy a full jury verdict without bankruptcy risk.
Commercial Liability Limit (Verified):$25,000,000.00
Underwriting Rating
A+ Tier88.4 / 100
Target Funding:$1,500,000.00
Estimated Damages:$18,000,000.00
Funding Ratio:8.3% (Conservative)
Target Net IRR:24.5%
Agreed Return Multiple:2x
Non-Recourse Structure
Funding is contingent strictly on settlement or verdict proceeds. If litigation terminates with zero recovery, the claimant and counsel owe $0.00.